Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, Gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts
Blood (2008)
  • Roland B. Walter, Fred Hutchinson Cancer Research Center
  • Kelli M. Boyle, Fred Hutchinson Cancer Research Center
  • Frederick R. Appelbaum, Fred Hutchinson Cancer Research Center
  • Irwin D. Bernstein, Fred Hutchinson Cancer Research Center
  • John M. Pagel, Fred Hutchinson Cancer Research Center
Link
Disciplines
Publication Date
May 1, 2008
DOI
10.1182/blood-2008-01-133785
Citation Information
Roland B. Walter, Kelli M. Boyle, Frederick R. Appelbaum, Irwin D. Bernstein, et al.. "Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, Gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts" Blood Vol. 111 Iss. 9 (2008) p. 4813 - 4816
Available at: http://works.bepress.com/john-pagel/236/